Document is current

Article History

Received: 12 February 2025

Accepted: 5 March 2026

First Online: 13 March 2026

Declarations

:

: All patients recruited for this initiative provided informed consent to participate and authorized the processing of their personal data (e-mail address, age, sex, geographical origin, medical condition, years since diagnosis) and their responses to the questionnaire provided during the session. The data collection process was conducted in full compliance with the current Spanish legislation on personal data protection, specifically Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights ( ). This study consisted of qualitative interviews with ATTR patients developed for this study, without involving clinical interventions or the collection of sensitive health data. According to Spanish research regulations, including Law 14/2007 of July 3 on Biomedical Research and Royal Decree 1090/2015 of December 4, which primarily govern research involving clinical interventions or medicinal products, ethical committee approval was not required for this type of study. All procedures were conducted following the principles outlined in the Declaration of Helsinki.

: Not applicable.

: In the last three years, the following conflicts of interest have been disclosed: LG has received research grants from Alnylam, consulting fees from Alnylam, AstraZeneca and Pfizer, speaker fees and travel/congress assistance from Alnylam and Pfizer, and equipment/materials support from Pfizer; MAL has received speaker/lecturer honoraria from Alnylam, Pfizer and Takeda, meeting attendance/travel support from Takeda, and honoraria for participation in data safety monitoring/advisory boards; TR-V has received consulting fees from Alnylam and Pfizer, and honoraria for participation in lectures/presentations from AstraZeneca; IM declares no conflict of interest; JFS has received research grants from Alnylam, consulting fees from Alnylam, AstraZeneca and Pfizer, speaker fees and travel/congress assistance from Alnylam and Pfizer, and equipment/materials support from Pfizer.